Abbott eyes lung cancer diagnostics
This article was originally published in The Gray Sheet
German biotech firm BioVision will receive research payments and possible milestone and royalty compensation under a new biomarker development agreement with Abbott. Promising peptide- and protein-based markers for lung cancer identified by BioVision could make their way onto Abbott platforms...
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.